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ABSTRACT
Introduction: Secukinumab and adalimumab are
approved for adults with active psoriatic arthritis
(PsA). In the absence of direct randomized
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controlled trial (RCT) data, matching-adjusted
indirect comparison can estimate the comparative
effectiveness in anti-tumor necrosis factor (TNF)naı̈ve populations.
Methods: Individual patient data from the
FUTURE 2 RCT (secukinumab vs. placebo;
N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs.
placebo; N = 313). Logistic regression determined adjustment weights for age, body weight,
sex, race, methotrexate use, psoriasis affecting C 3% of body surface area, Psoriasis Area
and Severity Index score, Health Assessment
Questionnaire Disability Index score, presence
of dactylitis and enthesitis, and previous antiTNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24,
and 48 (nonplacebo-adjusted).
Results: After matching, the effective sample
size for FUTURE 2 was 101. Week 12 American
College of Rheumatology (ACR) response rates
were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and
50 response rates were higher for secukinumab
150 mg than for adalimumab (P = 0.017,
P = 0.033), as was ACR 50 for secukinumab
300 mg (P = 0.030). Week 24 ACR 20 and 50
were higher for secukinumab 150 mg than for
adalimumab (P = 0.001, P = 0.019), as was ACR
20 for secukinumab 300 mg (P = 0.048). Week
48 ACR 20 was higher for secukinumab 150 and
300 mg than for adalimumab (P = 0.002,
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P = 0.027), as was ACR 50 for secukinumab
300 mg (P = 0.032).
Conclusions: In our analysis, patients with PsA
receiving secukinumab were more likely to
achieve higher ACR responses through 1 year
(weeks 16–48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from
FUTURE 2 and thus should be considered
interim until the ongoing head-to-head RCT
EXCEED can validate these findings.
Funding: Novartis Pharma AG.
Keywords: Adalimumab;
Comparative
effectiveness;
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INTRODUCTION
For patients with active psoriatic arthritis (PsA),
international recommendations such as those
of the European League Against Rheumatism
(EULAR) [1, 2] and the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) [3] advise the use of biologic diseasemodifying antirheumatic drugs (bDMARDs)
when a patient’s response to conventional
synthetic DMARDs (csDMARDs; bDMARD and
csDMARD defined according to EULAR) is
inadequate. Historically, bDMARDs have targeted tumor necrosis factor (TNF) but now also
include antibodies targeting interleukin 12/23
and interleukin-17A (IL-17A) [4].
At least seven bDMARDs, mainly targeting
TNF, are now available for use in patients with
PsA. Thus, to help optimize treatment plans for
this long-term chronic condition, appropriately
powered head-to-head (H2H) randomized controlled trials (RCTs) comparing the efficacy and
safety of different bDMARDs are required. One
such trial is EXCEED, directly comparing the
long-term (52 weeks) efficacy and safety of the
fully human anti-IL-17A secukinumab with the
anti-TNF adalimumab [5]. Until data from this
trial become available, clinicians and health
technology assessment bodies may need to
resort to adjusted indirect comparisons of these
medicines as the best available evidence to
inform treatment decisions.
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One means of bridging this evidence gap is
through the use of inferential analyses such as
network meta-analysis [6, 7]. Such techniques
are useful when there is a common comparator
arm between RCTs (or in general a connected
network of studies [6]) and similar study populations, but the methodology is limited by further cross-trial differences, potential lack of
common comparators (or connected networks),
sensitivity to modeling assumptions, and disparities in definitions of outcome measures
[6, 7]. Matching-adjusted indirect comparison
(MAIC) incorporates individual patient data
(IPD) to address several of the limitations that
arise in comparisons based only on aggregate
data; thus, it can simulate more closely how
treatments may have performed if compared
directly [8–10].
MAIC uses IPD from one or multiple studies
for one treatment to match clinically relevant
baseline aggregate characteristics from a published study of another treatment. The patient
characteristics from the IPD are adjusted, using
a frequently used form of propensity score
matching, so that the mean baseline characteristics match those of the aggregate data. This
process results in a reduced effective sample size
(ESS) for the IPD arms. Outcomes from common
comparator arms such as placebo can be used to
validate the matching. After matching, the
mean of the recalculated matched IPD is compared with the observed mean for the aggregate
data from the published study [8].
The results from MAIC in PsA and other
conditions have been reported in peer-reviewed
publications [11–13], and MAIC has been
acknowledged as a valid methodological tool by
health-technology assessment agencies [10, 14].
MAIC is evolving and becoming a useful complementary technique to meta-analysis in providing comparative effectiveness evidence,
especially when such information is unavailable
from direct clinical trial comparisons [8]. MAIC
has previously been applied to assess the comparative effectiveness of adalimumab versus
etanercept [11] and adalimumab versus etanercept or infliximab in patients with psoriasis and
PsA, respectively [13]. A short- to midterm
MAIC analysis (24 weeks) between adalimumab
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and secukinumab in patients with PsA was
recently published [12].
Our study sought to address the evidence gap
in the comparative effectiveness of up to 1 year
biologic treatment of IL-17A versus anti-TNF in
patients with PsA. Therefore, MAIC was used to
compare adalimumab and secukinumab based
on common primary and secondary outcome
measures from the ADEPT [15–17] and FUTURE
2 [18] trials.

METHODS
Systematic Literature Review
A systematic literature review (SLR) was conducted in September 2014 and updated on
November 6, 2015 to identify all relevant clinical evidence for the use of secukinumab and
relevant comparators in the treatment of adult
patients with PsA. This article is based on previously conducted studies and does not involve
any new studies of human or animal subjects.
The SLR eligibility criteria are outlined in
Table S1, and the Preferred Reporting Items for
Systematic
Reviews
and
Meta-analyses
(PRISMA) flow chart is shown in Fig. S1, both in
the supplementary material. Following full-text
screening, 29 trials were suitable for inclusion
according to the eligibility criteria. For the
purpose of this analysis, adalimumab is considered the comparator of interest to secukinumab, because of its equivalent efficacy to
other anti-TNFs and widespread clinical use
[19].
Of the 29 trials, 19 included neither secukinumab nor adalimumab and were excluded
from this MAIC. The remaining ten studies are
shown in Table S2 in the supplementary material with the reasons for exclusion. Of these ten
trials, six investigated secukinumab (CLEAR
[20], ERASURE [21], FUTURE 1 [22], FIXTURE
[21], FUTURE 2 [18], and McInnes et al. [23]),
and the remaining four studied adalimumab
(ADEPT [15], Behrens et al. [24], Genovese et al.
[25], and van Kuijk et al. [26]). Three of these
trials, CLEAR, ERASURE, and FIXTURE, were
then excluded because they included patients
with moderate-to-severe psoriasis, of whom
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only a subgroup had concomitant PsA. The
study by Behrens et al. [24] was excluded
because it was an observational study. Genovese
et al. [25] was excluded because the randomized
placebo-controlled stage lasted only until week
12, and McInnes et al. [23] was excluded
because it was a phase 2 study. Van Kuijk et al.
[26] was excluded because the study was
restricted to synovial biopsy analyses. Finally,
the phase 3 study FUTURE 1 [22] was excluded
because only one of two licensed subcutaneous
maintenance doses of secukinumab was investigated (150 mg) and it used an intravenous
loading method.
Source Data
FUTURE 2 (NCT01752634) was a phase 3,
double-blind RCT in adults with active PsA
(Fig. 1) [18, 27–29]. Patients were randomized to
subcutaneous secukinumab (300, 150, or
75 mg) or placebo, once per week from baseline
to week 4 and every 4 weeks thereafter [18]. The
primary endpoint was the proportion of
patients achieving a 20% or greater improvement in the American College of Rheumatology
(ACR 20) response criteria at week 24 [30].
Patients receiving concomitant corticosteroid or
methotrexate (MTX) medication or who had a
previous inadequate response or inability to
tolerate up to three different anti-TNF therapies
(anti-TNF-IR) could enroll. These biologicexperienced patients made up 35% of the total
study population. At week 16, patients were
assessed as either responders (C 20% improvement from baseline in swollen and tender joint
counts) or nonresponders. Placebo-treated
patients were rerandomized in a 1:1 ratio to
secukinumab 150 or 300 mg every 4 weeks from
week 16 (nonresponders) and week 24
(responders).
ADEPT was a phase 3, double-blind RCT in
adults with active PsA (Fig. 1) [15]. Patients were
randomized to receive subcutaneous adalimumab 40 mg or placebo every other week. The
primary endpoints were the proportion of
patients achieving an ACR 20 response at
week 12 and the change in modified total Sharp
score of structural damage on radiographs of the
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Fig. 1 FUTURE 2 and ADEPT trial designs relative to
MAIC analysis. aPatients who had a C 20% improvement
compared with baseline in TJC and SJC. bPatients who
had a \ 20% improvement compared with baseline in
TJC and SJC. c153 patients were randomized; however,
two patients were not given adalimumab. Analyses were
performed on 151 patients who received adalimumab.
d
Patients who completed the 24-week double-blind period
were eligible for the open-label extension study (adalimumab 40 mg EOW). Patients who failed to demonstrate
a C 20% improvement compared with baseline in TJC
and SJC (study week 36) were allowed to increase the
adalimumab dosage to 40 mg weekly. ePatients who did
not demonstrate a C 20% improvement compared with
baseline in ACR 20 could receive rescue therapy (corticosteroids and/or csDMARDs). The time points (weeks
from ﬁrst subcutaneous injection) at which postmatching
outcome comparisons were made are indicated. ACR
outcomes were compared at week 12 (placebo-adjusted)

and at weeks 16, 24, and 48/52 (nonplacebo-adjusted).
The placebo-adjusted phase comparison was valid only
until week 12 (shown by yellow rectangle) because of the
rescue therapy design component of ADEPT. Numbers in
gray denote the ITT populations. All FUTURE 2
secukinumab outcomes were ITT to week 52. ADEPT
adalimumab ITT outcome data were maintained until
week 48 using published data [16]. Open-label extension
adalimumab week 36 dose increase to weekly adalimumab
(n = 15 and n = 23 in the original adalimumab and
placebo groups, respectively) was classiﬁed as NRI. ACR
American College of Rheumatology, csDMARD conventional synthetic DMARD, DMARD disease-modifying
antirheumatic drug, EOW every other week, ITT intentto-treat, MAIC matching-adjusted indirect comparison,
mTSS modiﬁed total Sharp score, NRI nonresponder
imputation, R randomization, SJC swollen joint count,
TJC tender joint count

hands and feet at week 24. Patients could enroll
if they were receiving concomitant MTX medication as long as the dose was stable for at least

3 months and was not higher than 30 mg per
week. Patients who had previously used any
form of anti-TNF biologic were excluded. After
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week 12, patients whose swollen and tender
joint counts did not decrease by at least 20% on
two consecutive visits could receive rescue
therapy with corticosteroids or csDMARDs [15].
All patients who completed the initial 24 weeks
of treatment were eligible to receive adalimumab 40 mg as part of an open-label extension study [15, 16].
MAIC Methodology
The MAIC methodology is graphically summarized in Fig. 2.
Selection of Baseline Characteristics
for Matching
Matching variables were selected for their
potential influence on key efficacy outcomes on
joints and skin; there was no specific matching
for baseline safety parameters. The clinical relevance of potential matching variables was discussed among the authors, who include clinical
experts in the treatment of active PsA, as well as
health economics and comparative effectiveness
research experts. In addition, correlation analyses of patient baseline characteristics with ACR
20, 50, and 70 responses achieved at week 48 in
FUTURE 2 informed the choice of matching
variables (Tables S3–S5 in the supplementary
material). This strategy is in line with a recent
National Institute for Health and Care Excellence (NICE) guidance on MAIC methodology
(NICE Decision Support Unit technical support
document 18 [NICE DSU TSD 18]) [10], which
recommends justifying the choice of matching
parameter by clinical expert advice and/or
empirical identification of all prognostic variables and effect modifiers in the weighting
model (depending on whether anchored [all
effect modifiers] or unanchored [all effect modifiers and prognostic variables] comparisons are
being made). Although NICE is geared to a UK
payer perspective, its MAIC guidelines were
constructed by a group of globally acknowledged academic experts in comparative statistics
and represent the only methodologically
advanced guidelines published to date.
Two scenarios were developed that differed
in the combination of matching variables
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included. First, a principal analysis replicated
the baseline characteristics of a previous MAIC
between the same two trials [12], including
established prognostic variables, but updated to
include parameters identified by logistic
regression analysis as having the greatest impact
on ACR criteria outcomes (prognostic variables
or effect modifiers). One additional baseline
parameter, biologic-experienced (i.e., previous
inadequate response or intolerance to anti-TNF
exposure), was identified as a key variable to
have an impact on responses (ACR 20 odds ratio
[95% confidence interval (CI)], 0.431 [0.265,
0.701]; P = 0.0007) and therefore included in
the principal analysis (Table 1). Similarly, data
from the trial ACCLAIM, an open-label study,
have shown that patients previously exposed to
a biologic therapy have a lower response with
adalimumab than those who are biologic-naı̈ve
[31]. The sensitivity analysis (Table S6 in the
supplementary material) used a more comprehensive set of matching variables and included
all of those used in the principal analysis plus
three more clinically relevant baseline characteristics to increase the matching stringency:
PsA disease duration (time since diagnosis),
swollen joint count (SJC), and C-reactive protein (CRP) levels.
Matching and Adjusting IPD to Published
Aggregate Data
IPD from the pooled secukinumab arms of the
FUTURE 2 trial (75, 150, and 300 mg) were
weighted to match the selected patient baseline
characteristics for the adalimumab arm of
ADEPT. The adalimumab data were reported
aggregates taken from the trial publications.
Only secukinumab 150 and 300 mg outcomes
were compared with adalimumab outcomes
because these are the doses licensed in PsA. The
methodology was based on Signorovitch et al.
[11], subsequent studies [8, 13, 32], and NICE
DSU TSD 18 [9, 10]. SAS version 9.4 and R version 3.2.1 were used for the analysis. The
regression results were used to weight patients
in FUTURE 2, using the method of moments
(mean only) so that each patient’s weight corresponded to his or her relative propensity for
enrolling in FUTURE 2 versus ADEPT. After this
matching process, the weighted mean baseline
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Fig. 2 MAIC methodology using a hypothetical example.
Two treatments of interest have been identiﬁed (by SLR):
one treatment is examined in study A and another
treatment in study B. The researcher has access to IPD for
study B but only aggregate published data for study A. Step
1: relevant clinical baseline parameters are selected for
matching following consultation with clinical and statistical experts. Step 2: the similarity of IPD baseline
characteristics with those of the aggregate study A
characteristics (color-coded in this example: red, high
through to green, low) will dictate how inﬂuential that
IPD will be within the matching process. Step 3: matching
is performed by application of weights to each IPD
(derived by logistic regression) using a matching algorithm
similar to propensity score matching. The method of
moment was applied using the quasi-Newton optimization
‘ BFGS’’ implemented in the R function optim, as
recommended [9, 10]. IPD with a closer match to the
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aggregate study A baseline characteristics are ‘ upweighted,’’
while those with a poor match are ‘ downweighted.’’ In this
example, this leads to an ESS of 4 (rounded to the nearest
integer to avoid confusion) using the equation shown. Step
4: study B mean IPD population baseline characteristics
match the mean of study A and outcomes can now be
compared directly between the two studies. The same
weights are used to recalculate each IPD outcome, and
then the mean recalculated study B IPD outcomes are
directly compared with the published aggregate study A
outcomes using appropriate statistical tests. aSome IPD
when highly incompatible with the target trial population
are given weights that are extremely small (weighting is on
a quantitative scale) and effectively act as a zero weight.
ESS effective sample size, IPD individual patient data,
MAIC matching-adjusted indirect comparison, SLR systematic literature review
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characteristics of the FUTURE 2 population
matched those reported for ADEPT, and the
sample size of FUTURE 2 was reduced to a lower
ESS.
Comparing Outcomes Using Recalculated
Patient Data
The weights were used to recalculate outcomes
for each IPD, and these were used to estimate
the comparative effectiveness of secukinumab
and adalimumab [8].
Analyses
Missing Data Handing
In ADEPT, all published outcomes were from
the intention-to-treat (ITT) population. All
missing binary outcome data (ACR 20, 50, and
70) were handled using nonresponder imputation (NRI) [15, 16], while missing patient-reported outcomes (PROs; continuous) were
handled using last observation carried forward
(LOCF) methodology. In FUTURE 2 [18], outcomes were from the ITT population. All missing binary outcome data (ACR 20, 50, and 70)
were derived using NRI, while all missing PRO
data (continuous) were derived using LOCF to
match the available data from ADEPT. It is
worth highlighting that our analysis did not use
penalties at week 24 for early non-responders,
thereby removing ‘bias’ when comparing our
results with those for adalimumab and making
our approach different from the numbers
reported in the main FUTURE 2 publications.
Outcomes
Outcomes selected for comparison were in line
with the Outcomes Measures in Rheumatology
(OMERACT) [33, 34] and GRAPPA [35] recommendations on outcome measures that should
be included in PsA clinical trials [33, 34].
• ACR response rates: ACR 20, 50, and 70
response rates were assessed at weeks 12, 16,
24, and 48 in both trials.
• PRO scores: mean change from baseline in
Health Assessment Questionnaire Disability
Index (HAQ-DI), Patient Global Assessment
(PGA), pain assessment, and the Functional
Assessment of Chronic Illness Therapy-

105

Fatigue (FACIT-F) score were included. Outcomes were reported at weeks 12, 24, and 48
in ADEPT so comparisons were feasible at
these time points; no data were available for
week 16 in ADEPT.
Placebo-Adjusted and Nonplacebo-Adjusted
Outcome Comparisons
The study designs of the trials (Fig. 1) specified
that patients randomized to placebo could
receive active treatment from week 16 in
FUTURE 2 or rescue therapy (corticosteroids or
csDMARDs) from week 12 in ADEPT; hence,
unbiased placebo-adjusted treatment comparisons were not possible after week 12. After week
12, outcomes from the adalimumab arm in
ADEPT were directly compared with outcomes
from the recalculated secukinumab arm of
FUTURE 2. This is similar to a comparison of
outcomes of two single-arm trials. In these situations, the use of MAIC may be the only way
to adjust for cross-trial differences and should
be preferred over naı̈ve unadjusted comparisons. Commonly used in observational studies
[36], this approach has been successfully
applied to previous MAIC analyses of RCTs,
such as when placebo comparisons were not
available or valid [37], to overcome placebo
crossover, or extrapolation beyond study end
[32, 38].
A week 12, placebo-adjusted comparison was
also made. In addition to providing meaningful
short-term placebo-adjusted data, the placebo
arms also act as a form of matching control,
because if the populations have been properly
matched (assuming no variables that impact on
placebo responses that cannot be controlled
through matching), there should be limited
cross-trial differences in placebo arm responses.
Pairwise Comparisons
For ACR outcomes, relative risk (RR; see Fig. S2
in the supplementary material) values were
estimated as the ratio of response rates (Table S7
in the supplementary material), and P values
(two-sided) for indirect treatment comparison
using RR were derived from the corresponding
Z-statistic. For placebo-adjusted comparisons,
RRs and corresponding standard errors were

n (%)

Anti-TNF-naı̈ve,

use, n (%)

Methotrexate

Previous treatment

enthesitis, n (%)

Presence of

dactylitis, n (%)

Presence of

mean (SD)

HAQ-DI score,

mean (SD)c

PASI score,

BSA, n (%)

affecting C 3%

Psoriasis

d

151 (100)

77 (51.0)

118 (37.7)

c

117 (37.4)

1.0 (0.6)

7.4 (6.0)

70 (46.4)

147 (97.4)

White, n (%)

Disease characteristics

66 (43.7)

86.0 (20.6)

48.6 (12.5)

(n = 151)

Female, n (%)

mean (SD)

Weight, kg,

mean (SD)

Age, years,

Demographics

Placebo

162 (100)

81 (50.0)

1.0 (0.7)

8.3 (7.2)

70 (43.2)

152 (93.8)

73 (45.1)

85.5 (16.5)

49.2 (11.1)

P \ 0.0001

63 (63.0)

P = 0.4385

46 (46.0)

P \ 0.0001

64 (64.0)

P = 0.4084

32 (32.0)

P = 0.0103

1.2 (0.6)

P \ 0.0001

16.2 (14.3)

P = 0.0709

58 (58.0)

P = 0.0130

90 (90.0)

P = 0.8402

45 (45.0)

P = 0.0479

91.2 (19.8)

P = 0.1826

46.5 (11.7)

(n = 100)

P \ 0.0001

67 (67.0)

P = 0.3523

45 (45.0)

P = 0.0044

56 (56.0)

P = 0.1592

46 (46.0)

P = 0.0001

1.3 (0.6)

P = 0.0014

11.9 (8.4)

P = 0.4028

41 (41.0)

P = 0.5508

96 (96.0)

P = 0.4101

49 (49.0)

P = 0.8140

85.4 (18.4)

P = 0.2940

46.9 (12.6)

(n = 100)

63 (64.3)

52 (53.1)

65 (66.3)

27 (27.6)

1.2 (0.7)

11.5 (8.3)

43 (43.9)

94 (95.9)

59 (60.2)

86.2 (19.8)

49.9 (12.5)

(n = 98)
(ESS = 36)

(n = 299)

P \ 0.0001

195 (65.2)

P = 0.3318

138 (46.2)

P \ 0.0001

188 (62.9)

P = 0.9938

111 (37.1)

P = 0.0009

1.2 (0.6)

P \ 0.0001

13.6 (11.6)

P = 0.4862

149 (49.8)

P = 0.0334

276 (92.3)

P = 0.3041

146 (48.8)

P = 0.4837

87.4 (19.7)

P = 0.2826

P = 1.000

36 (100)

P = 0.4281

(57.9)b

P = 0.8553

(34.9)

b

P = 0.6740

(32.5)

b

P = 1.000

1.0 (0.4)

P = 0.6079

8.2 (3.2)

P = 0.4882

(54.0)b

P = 0.9657

(96.2)

b

P = 0.5994

(38.4)

b

P = 0.4870

88.5 (12.7)

P = 0.4888

47.1 (7.0)

150 mg

SECa

47.3 (11.9)

SEC

Pooled

(n = 162)

40 mg
300 mg

SEC

Placebo

ADA
SEC

FUTURE 2

FUTURE 2

ADEPT

150 mg

After matching

Before matching

Table 1 Baseline characteristics before and after matching

P = 1.000

38 (100)

P = 0.6377

(54.0)b

P = 0.2786

(47.2)

b

P = 0.5272

(32.7)

b

P = 1.000

1.0 (0.4)

P = 0.7496

6.9 (3.5)

P = 0.8578

(44.1)b

P = 0.9952

(98.0)

b

P = 0.4438

(32.0)

b

P = 0.7972

85.1 (12.5)

P = 0.6811

49.5 (10.0)

(ESS = 38)

300 mg

SEC

27 (100)

(50.0)b

(37.7)

b

(37.4)

b

1.0 (0.4)

8.3 (3.2)

(43.2)b

(93.8)

b

(45.1)

b

85.5 (12.4)

49.2 (7.7)

(ESS = 27)

Placebo

P = 1.000

115 (100)

P = 1.000

(51.0)b

P = 1.000

(37.7)b

P = 1.000

(37.4)b

P = 1.000

1.0 (0.4)

P = 1.000

7.4 (3.2)

P = 1.000

(46.4)b

P = 1.000

(97.4)b

P = 1.000

(43.7)b

P = 1.000

86.0 (13.3)

P = 1.000

48.6 (8.3)

(ESS = 115)

SEC

Pooled
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9.8 (8.3)

14.3 (12.2)

1.4 (2.1)

PsA duration,
years, mean (SD)

SJC, mean (SD)

CRP, mg/dl,

Variables not used in the matching

30.8 (12.1)

51.1 (21.4)

47.1 (23.2)

30.8 (12.2)

48.8 (21.7)

48.1 (21.2)

46.6 (12.2)

33.3 (9.8)

25.8 (18.0)

1.4 (1.7)

14.3 (11.1)

9.2 (8.7)

26.6 (11.6)

58.9 (19.8)

62.0 (19.5)

40.6 (11.5)

36.1 (8.1)

24.1 (19.4)

1.4 (2.7)

11.9 (10.1)

6.5 (8.2)

28.6 (12.6)

57.7 (19.0)

60.7 (18.9)

43.6 (12.1)

36.9 (8.0)

20.2 (13.3)

1.1 (1.5)

11.2 (7.8)

7.4 (7.5)

29.2 (11.8)

55.4 (22.1)

57.6 (19.8)

44.0 (10.7)

37.4 (8.8)

23.4 (19.0)

0.8 (1.3)

12.1 (10.6)

7.3 (7.8)

(n = 98)

28.0 (11.6)

57.8 (19.9)

60.6 (19.2)

42.7 (11.7)

36.4 (8.1)

22.1 (16.5)

1.1 (1.9)

11.3 (9.0)

33.4 (6.8)

52.9 (12.1)

53.9 (11.9)

44.4 (8.5)

39.6 (4.9)

16.9 (9.9)

0.7 (0.7)

10.9 (6.5)

6.1 (5.8)

150 mg
(ESS = 36)

SECa
(n = 299)

6.8 (7.6)

SEC

Pooled

33.5 (9.0)

55.3 (13.8)

56.6 (13.5)

46.4 (8.6)

39.7 (5.7)

16.2 (7.6)

0.8 (0.8)

9.6 (4.1)

6.0 (4.8)

300 mg
(ESS = 38)

SEC

33.6 (6.0)

57.4 (11.5)

50.0 (11.1)

46.3 (5.3)

39.8 (4.9)

19.3 (11.3)

0.6 (0.4)

9.6 (4.4)

5.3 (3.3)

(ESS = 27)

Placebo

32.3 (7.6)

54.9 (13.2)

55.1 (13.0)

45.2 (8.1)

39.0 (5.1)

17.3 (8.5)

0.7 (0.7)

10.2 (5.7)

6.0 (5.1)

SEC
(ESS = 115)

Pooled

d

c

b

a

Pn

xi

2

i¼1

Percentages of patients with dactylitis and enthesitis are presented for the entire ADEPT study (pooled active treatment and placebo arms)

PASI data were collected only for patients with psoriasis affecting C 3% BSA

xi Þ
ð
Integer population (n) values are not available due to calculation of pooled SEC ESS using the equation: Pi¼1
n
2

Pooled SEC 75 mg (n = 99), 150 mg (n = 100), and 300 mg (n = 100) matched to ADA arm of ADEPT

Mental Component Summary, SF-36 PCS 36-item Short-Form Health Survey—Physical Component Summary, SJC swollen joint count, TJC tender joint count, TNF tumor necrosis factor

Disability Index, PASI Psoriasis Area and Severity Index, PGA patients’ global assessment, PsA psoriatic arthritis, SD standard deviation, SEC secukinumab, SF-36 MCS 36-item Short-Form Health Survey—

ADA adalimumab, BSA body surface area, CRP C-reactive protein, ESS effective sample size, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire

All P values were calculated for secukinumab versus adalimumab using t test for continuous variables and Chi-squared test for dichotomous variables

score, mean (SD)

FACIT-Fatigue

(SD)

of PsA pain, mean

Patient’s assessment

PGA, mean (SD)

mean (SD)

SF-36 MCS,

48.1 (10.2)

33.2 (9.9)

SF-36 PCS,

mean (SD)

23.9 (17.3)

TJC (SD)

mean (SD)

Placebo

(n = 162)

40 mg
(n = 151)
300 mg
(n = 100)

SEC

Placebo

ADA
SEC

FUTURE 2

FUTURE 2

ADEPT

150 mg
(n = 100)

After matching

Before matching

Table 1 continued
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calculated using the Bucher method [7]. Odds
ratios (ORs; see Fig. S2 in the supplementary
material) were also calculated for ACR responses
(Table S7 in the supplementary material). The
commonly used threshold of P \ 0.05 was
considered as a threshold for statistical significance (i.e., the incompatibility of observed data
with the null hypothesis position that there is
no difference between secukinumab and adalimumab for the outcome being compared). In
acknowledgment of the recent American Statistical Association statement on P values and
their preference to avoid such a threshold in
clinical research [39, 40], our data were also
analyzed using a more modern definition of the
strength of evidence that P values can provide
[41, 42] (0.1 [ P \ 0.001 as increasing evidence,
P B 0.001 as strong evidence against the null
hypothesis; Table S8 in the supplementary
material). For nonplacebo-adjusted comparisons, standard errors for RR values were estimated based on the information provided by a
fictitious 2 9 2 contingency table that shows
outcomes in the adalimumab arm of the ADEPT
trial and outcomes in the recalculated secukinumab arm of FUTURE 2 (with the ESS used as
the sample size for FUTURE 2). For the analysis
at week 12 (placebo-adjusted), RRs (and ORs) for
the secukinumab arm versus the placebo arm in
the reweighted FUTURE 2 population were
derived from a logistic regression model by
using generalized estimating equations with
robust standard errors as suggested in previous
work [9–11]. Generalized estimating equations
were fitted using PROC GENMOD in SAS.
For PRO scores, a 95% CI around mean
change scores of patients in the adalimumab
arm of the ADEPT trial was estimated using the
normal approximation. The P values for the
difference in mean change scores between
secukinumab and adalimumab were calculated
using a Z-statistic that divides the difference in
mean change scores by the combined standard
error.
Psoriasis Area and Severity Index Outcomes
We did not report comparative Psoriasis Area
and Severity Index (PASI) data, as the baseline
characteristic data for the ADEPT trial psoriasis
subgroup were not available. This meant that

uncontrolled imbalances could persist postmatching. Indeed, the high absolute differences
in PASI at baseline between studies lend further
weight to this limitation. It is also worth noting
that PASI outcome data were collected only in a
subgroup of patients in both studies (patients
with psoriasis affecting C 3% body surface
area), thus missing data in the non-PASI-matched population will further compound this
study bias.
Methotrexate Subgroup Analysis
The long-term efficacy of anti-TNFs has been
linked to concomitant MTX use [43]. MTX
prescribed in combination with an anti-TNF
may prolong anti-TNF survival [44] and dampen
the generation of neutralizing antibodies to
anti-TNFs [45–48]. Data from clinical registry
studies suggest that the role of MTX in promoting persistence varies between different
anti-TNFs [49].
Therefore, the impact of concomitant MTX
on IL-17A versus anti-TNF treatment was assessed by a subgroup analysis in which patients
were divided by concomitant MTX use at baseline. The issues surrounding the PASI data
(above) do not affect the MTX subgroup analysis, as these data were collected for all patients
(recorded as receiving or not receiving concomitant MTX) at the included timepoints.

RESULTS
Principal Analysis
Matching Baseline Characteristics
Table 1 shows the baseline characteristics of
patients from the FUTURE 2 secukinumab
(pooled 75, 150, and 300 mg arms, n = 299
before matching) and placebo (n = 98 before
matching) arms before and after matching
(150 and 300 mg only [75 mg was not used in
this comparison] and placebo) to the ADEPT
adalimumab (n = 151) and placebo (n = 162)
arms. Before matching, the study populations of
FUTURE 2 and ADEPT were heterogeneous with
FUTURE 2 including more difficult-to-treat
patients. One of the key differences between the
patient populations was that patients treated
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Fig. 3 ACR comparisons: principal analysis. P values are derived from relative risk values. Error bars show 95% conﬁdence
intervals. Numbers above bars are the absolute mean predicted responses (ADEPT) and the predicted mean responses
(FUTURE 2). Yellow background indicates that comparison was placebo-adjusted, white background indicates that
comparison was nonplacebo-adjusted. ACR 20/50/70 20%/50%/70% or greater improvement in the American College of
Rheumatology response criteria, ADA adalimumab, ESS effective sample size, SEC secukinumab

with secukinumab were either anti-TNF-naı̈ve
(65.2%) or anti-TNF-IR (34.8%), whereas all
patients treated with adalimumab were antiTNF-naı̈ve (100%). After matching IPD from
FUTURE 2 to ADEPT, all patients treated with
secukinumab (or placebo) were anti-TNF-naı̈ve
(100%). Another key prematch dissimilarity

between trials was baseline PASI score and a
more severe HAQ-DI, indicating higher functional disability of the patient population in
FUTURE 2.
Achieving homogeneity between the two
populations reduced the sample size; the ESSs
for FUTURE 2 after matching were 36
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Table 2 Comparison of principal and sensitivity analyses (relative risks)
Principal analysis (SEC vs. ADA)

Sensitivity analysis (SEC vs. ADA)

ADA 40 mg, n = 151; PBO, n = 162

ADA 40 mg, n = 151; PBO, n = 162

SEC 150 mg, ESS = 36; PBO, ESS = 27

SEC 150 mg, ESS = 15; PBO, ESS = 20

SEC 300 mg, ESS = 38; PBO, ESS = 27

SEC 300 mg, ESS = 25; PBO, ESS = 20

ACR 20

ACR 20

ACR 50

ACR 70

ACR 50

ACR 70

Week 12, placebo-adjusted data (SEC 150 mg)
0.69 (0.34, 1.43)

0.91 (0.23, 3.60)

0.68 (0.07, 6.22) 1.06 (0.39, 2.92)

10.44 (1.80, 60.56) 5.99 (0.56, 63.79)
P = 0.009

Week 12, placebo-adjusted data (SEC 300 mg)
0.61 (0.29, 1.27)

0.97 (0.25, 3.79)

0.50 (0.05, 4.93) 0.94 (0.34, 2.61)

16.01 (2.95, 86.84) 6.85 (0.64, 73.92)
P = 0.001

Week 16 (SEC 150 mg)
1.34 (1.05, 1.70) 1.54 (1.03, 2.30) 0.90 (0.43, 1.92) 1.44 (1.08, 1.92) 1.67 (0.99, 2.80)
P = 0.017
P = 0.033
P = 0.014
P = 0.055

0.91 (0.30, 2.73)

Week 16 (SEC 300 mg)
1.18 (0.90, 1.54)

1.54 (1.04, 2.29) 0.91 (0.44, 1.89) 1.35 (1.03, 1.76) 1.63 (1.05, 2.52)
P = 0.030
P = 0.030
P = 0.029

0.92 (0.39, 2.20)

Week 24 (SEC 150 mg)
1.42 (1.15, 1.75) 1.50 (1.07, 2.10) 1.59 (0.95, 2.67) 1.46 (1.12, 1.91) 1.52 (0.96, 2.42)
P = 0.001
P = 0.019
P = 0.005

1.54 (0.74, 3.23)

Week 24 (SEC 300 mg)
1.27 (1.00, 1.62) 1.05 (0.69, 1.62)
P = 0.048

0.99 (0.52, 1.90) 1.40 (1.10, 1.78) 1.08 (0.66, 1.79)
P = 0.006

1.00 (0.47, 2.17)

1.09 (0.64, 1.85) 1.41 (1.05, 1.89) 1.55 (1.04, 2.30)
P = 0.022
P = 0.029

1.29 (0.65, 2.56)

Week 48 (SEC 150 mg)
1.41 (1.14, 1.76) 1.31 (0.93, 1.83)
P = 0.002
Week 48 (SEC 300 mg)
1.31 (1.03, 1.66) 1.41 (1.03, 1.92) 1.44 (0.93, 2.24) 1.45 (1.15, 1.83) 1.66 (1.23, 2.24)
P = 0.027
P = 0.032
P = 0.002
P < 0.001

1.68 (1.05, 2.66)
P = 0.029

Data are shown as relative risk (95% conﬁdence interval)
P values (bold text when signiﬁcant, i.e., P \ 0.05) were derived from relative risk values using the Z-statistic. All statistically
signiﬁcant observations made were in favor of SEC compared with ADA. No signiﬁcantly higher outcomes for ADA
compared with SEC were observed
ACR 20/50/70 20%/50%/70% or greater improvement in the American College of Rheumatology response criteria, ADA
adalimumab, ESS effective sample size, PBO placebo, SEC secukinumab

ESS = 27)

n = 162)

5.9 (3.7, 8.1)

(- 30.3, - 18.9)

- 24.6

(- 25.9, - 14.1)

- 20.0

(- 0.41, - 0.19)

8.8 (6.3, 11.2)

(- 25.4, - 12.3)

- 18.9

(- 32.4, - 19.1)

- 25.8

(- 0.32, - 0.09)

- 0.20

PBO,

PBO,

- 0.30

ESS = 36;

n = 151;

6.2 (3.5, 8.8)

(- 22.7, - 8.5)

- 15.6

(- 32.1, - 18.4)

- 25.2

(- 0.36, - 0.12)

- 0.24

ESS = 27)

PBO,

ESS = 38;

(SEC,

7.1 (5.5, 8.7)

(- 28.5, - 19.5)

- 24.0

(- 25.8, - 16.4)

- 21.1

(- 0.48, - 0.32)

- 0.40

(n = 151)

7.8 (6.1, 9.6)

P = 0.039a

(2 34.6, 2 26.3)

2 30.4

P = 0.005a

(2 34.6, 2 25.9)

2 30.2

P = 0.046a

(20.62, 20.43)

2 0.53

(ESS = 36)

150 mg

SEC

P = 0.021b

4.5 (3.0, 6.0)

(- 29.4, - 19.5)

- 24.5

(- 32.9, - 22.9)

- 27.9

(- 0.61, - 0.42)

- 0.52

(ESS = 38)

300 mg

SEC

6.7 (5.6, 7.8)

(- 27.1, - 20.9)

- 24.0

(- 25.6, - 19.2)

- 22.4

(- 0.48, - 0.32)

- 0.40

(n = 151)

40 mg

ADA

Week 48

7.6 (6.1, 9.1)

(- 32.5, - 22.9)

- 27.7

(- 32.4, - 22.6)

- 27.5

P = 0.037a

(2 0.64, 2 0.44)

2 0.54

(ESS = 36)

150 mg

SEC

5.6 (4.0, 7.1)

(- 33.0, - 22.8)

- 27.9

P = 0.016a

(2 34.1, 2 24.7)

2 29.4

(- 0.62, - 0.41)

- 0.52

(ESS = 38)

300 mg

SEC

c

b

a

Week 48 FACIT-Fatigue score comparisons were made between week 48 (ADEPT) and week 52 (FUTURE 2)

Statistical signiﬁcance in favor of ADA

Statistical signiﬁcance in favor of SEC

global assessment, SEC secukinumab, VAS visual analog scale

ADA adalimumab, ESS effective sample size, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire Disability Index, LOCF last observation carried forward, PBO placebo, PGA patient’s

Data are shown as mean change from baseline (95% conﬁdence interval)

scorec

Fatigue

FACIT-

Pain (VAS)

(0–10 cm)

PGA

score

HAQ-DI

(SEC,

(ADA,

40 mg

ADA

150 mg

40 mg
300 mg

SEC

ADA
SEC

Week 24

Week 12, placebo-adjusted

Table 3 Principal analysis: patient-reported outcome comparisons (LOCF)
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(secukinumab 150 mg), 38 (secukinumab
300 mg), and 27 (placebo).
It has been proposed that outcomes from
common comparator arms such as placebo can
be used to validate the matching process, i.e., a
good match should lead to equivalent or nearequivalent placebo arm responses [8, 50]. Placebo arm ACR 20 (week 12) responses were
14.2% (ADEPT) and 26.7% (FUTURE 2); ACR 50
responses were 3.7% (ADEPT) and 4.3%
(FUTURE 2). Given that ACR 50 is a significantly
more stringent outcome than ACR 20, the near
equivalence of the placebo response between
ADEPT and recalculated FUTURE 2 suggests a
good match.

ACR Response Rates
Figure 3 and Table 2 show the ACR 20, 50, and
70 response rates in the principal analysis. At
week 12, there were no statistically significant
differences in any ACR placebo-adjusted
response rates between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates
were significantly higher for secukinumab
150 mg than for adalimumab [RR, 1.34 (95% CI:
1.05, 1.70); P = 0.017 and RR, 1.54 (95% CI:
1.03, 2.30); P = 0.033, respectively], as was the
ACR 50 response rate for secukinumab 300 mg
over adalimumab [RR, 1.54 (95% CI: 1.04, 2.29);
P = 0.030]. Week 24 ACR 20 and 50 response
rates were significantly higher for secukinumab

Fig. 4 Methotrexate subgroup analysis: MAIC-predicted
ACR response rates at weeks 24 and 48 in patients
(a) receiving and (b) not receiving methotrexate at
baseline. P values are derived from RR values. Error bars
show 95% conﬁdence intervals. Numbers above bars show
the absolute mean predicted responses (ADEPT) and the

predicted mean responses (FUTURE 2). ACR 20/50/70
20%/50%/70% or greater improvement in the American
College of Rheumatology response criteria, ADA adalimumab, ESS effective sample size, MAIC matchingadjusted indirect comparison, RR relative risk, SEC
secukinumab
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150 mg than for adalimumab [RR, 1.42 (95% CI:
1.15, 1.75); P = 0.001 and RR, 1.50 (95% CI:
1.07, 2.10); P = 0.019, respectively], as was the
ACR 20 response rate for secukinumab 300 mg
over adalimumab [RR, 1.27 (95% CI: 1.00, 1.62);
P = 0.048]. The week 48 ACR 20 response rate
was significantly higher for secukinumab
150 mg than for adalimumab [RR, 1.41 (95% CI:
1.14, 1.76); P = 0.002], as were the ACR 20 and
50 response rates for secukinumab 300 mg over
adalimumab [RR, 1.31 (95% CI: 1.03, 1.66);
P = 0.027 and RR, 1.41 (95% CI: 1.03, 1.92);
P = 0.032, respectively].
PRO Scores
Table 3 shows the principal analysis comparison
of HAQ-DI, PGA, pain assessment, and FACIT-F
scores. At week 12, there were no significant
differences in any continuous outcome data
between secukinumab and adalimumab. No
ADEPT data were available for week 16. At week
24, treatment with secukinumab 150 mg resulted in significantly greater improvements in
HAQ-DI, PGA, and pain scores relative to adalimumab (– 0.53 vs. – 0.40, P = 0.046; – 30.2 vs.
– 21.1, P = 0.005; and – 30.4 vs. – 24.0,
P = 0.039, respectively). Adalimumab therapy
resulted in a significantly greater improvement
in FACIT-F score relative to secukinumab
300 mg (7.1 vs. 4.5, P = 0.021), although there
was no difference relative to secukinumab
150 mg. At week 48, treatment with secukinumab 150 mg resulted in a significantly
greater improvement in HAQ-DI score, while
secukinumab 300 mg had a significantly greater
improvement in PGA score relative to adalimumab (– 0.54 vs. – 0.40, P = 0.037 and – 29.4
vs. – 22.4, P = 0.016, respectively).
Methotrexate Subgroup Analysis
Concomitant MTX subgroup data from ADEPT
were available only at weeks 24 and 48. After
matching, the sample sizes at week 24 for the
subgroup receiving MTX (at baseline) were:
adalimumab, n = 77; secukinumab 150 mg,
ESS = 19; and secukinumab 300 mg, ESS = 17,
while the sample sizes for the subgroup not
receiving MTX (at baseline) were: ADEPT,

113

n = 74; secukinumab 150 mg, ESS = 17; and
secukinumab 300 mg, ESS = 22.
Figure 4 and Table 4 show the ACR response
rates for the principal analysis MTX subgroup
comparison. At week 24, for patients receiving
MTX at baseline, ACR 20 response rates were
higher with secukinumab 150 mg [RR, 1.55
(95% CI: 1.18, 2.05); P = 0.002] than with
adalimumab. For patients not receiving MTX at
baseline, ACR 20 response rates were higher
with secukinumab 300 mg than with adalimumab [RR, 1.33 (95% CI: 1.00, 1.77);
P = 0.048]. At week 48, for patients receiving
MTX at baseline, ACR 20 response rates were
higher with secukinumab 150 mg [RR, 1.37
(95% CI: 1.06, 1.76); P = 0.015] than with
adalimumab. For patients not receiving MTX at
baseline, ACR 20 [RR, 1.53 (95% CI: 1.11, 2.11);
P = 0.010], ACR 50 [RR, 1.78 (95% CI: 1.18,
2.67); P = 0.006] and ACR 70 [RR, 1.88 (95% CI:
1.12, 3.17); P = 0.017] response rates were
higher with secukinumab 300 mg than with
adalimumab.
Sensitivity Analysis
Matching Baseline Characteristics
The sensitivity analysis matched for the same
parameters as the principal analysis, with the
addition of three variables (PsA disease duration, SJC, and CRP), as shown in Table S6 in the
supplementary material. The ESSs in FUTURE 2
after matching were 15 (secukinumab 150 mg),
25 (secukinumab 300 mg), and 20 (placebo).
Placebo arm ACR 20 (week 12) response rates
were 14.2% (ADEPT) and 19.3% (secukinumab
150 mg, FUTURE 2); and ACR 50 responses were
3.7% (ADEPT) and 0.3% (FUTURE 2). The ACR
20 data suggest that this match was even closer
than that of the principal analysis. There
appears to be a lower ACR 50 placebo response
with secukinumab 150 mg relative to adalimumab, although the low ESS and low values
suggest this is a less reliable observation than
the ACR 20 comparison.
ACR Response Rates
Results were broadly consistent with those of
the principal analysis (Table 2), in that ACR 20

1.27 (0.92, 1.77)

1.78 (1.18, 2.67) P = 0.006

1.53 (0.93, 2.50)

1.14 (0.68, 1.90)

1.43 (0.89, 2.30)

1.88 (1.12, 3.17) P = 0.017

1.50 (0.78, 2.86)

1.15 (0.51, 2.59)

1.63 (1.18, 2.24) P = 0.003

1.24 (0.67, 2.31)

1.39 (1.04, 1.85) P = 0.027

1.23 (0.75, 2.00)

1.92 (1.28, 2.88) P = 0.002

1.50 (0.74, 3.02)

1.18 (0.68, 2.04)

1.64 (0.93, 2.89)

1.46 (0.93, 2.28)

1.55 (0.99, 2.43)

0.97 (0.40, 2.36)

1.43 (0.69, 2.96)

P values (bold text when signiﬁcant, i.e., P \ 0.05) were derived from relative risk values using the Z-statistic
ACR 20/50/70 20%/50%/70% or greater improvement in the American College of Rheumatology response criteria, ADA adalimumab, ESS effective sample size, SEC secukinumab

Data are shown as relative risk (95% conﬁdence interval)

1.53 (1.11, 2.11) P = 0.010

Week 48 (SEC 300 mg)

1.42 (0.97, 2.07)

Week 48 (SEC 150 mg)

1.33 (1.00, 1.77) P = 0.048

Week 24 (SEC 300 mg)

1.46 (0.67, 3.22)

ACR 20

ACR 20

Week 24 (SEC 150 mg)

SEC 300 mg, ESS = 17

SEC 300 mg, ESS = 22

ACR 50

SEC 150 mg, ESS = 7

SEC 150 mg, ESS = 17

ACR 50

ADA 40 mg, n = 74 (week 24); n = 76 (week 48)

1.30 (0.93, 1.83)

1.50 (1.16, 1.92) P = 0.002

1.41 (0.95, 2.10)

ADA 40 mg, n = 74 (week 24); n = 76 (week 48)

ACR 70

0.89 (0.38, 2.08)

0.80 (0.34, 1.88)

0.83 (0.28, 2.47)

1.68 (1.26, 2.25) P < 0.001

Sensitivity analysis (SEC vs. ADA)

1.07 (0.65, 1.77)

1.14 (0.72, 1.80)

0.89 (0.42, 1.88)

1.58 (0.97, 2.57)

Principal analysis (SEC vs. ADA)

(b)

1.11 (0.77, 1.59)

Week 48 (SEC 300 mg)

1.37 (1.06, 1.76) P = 0.015

Week 48 (SEC 150 mg)

1.16 (0.77, 1.76)

Week 24 (SEC 300 mg)

1.55 (1.18, 2.05) P = 0.002

1.79 (0.89, 3.59)

ACR 20

ACR 20

Week 24 (SEC 150 mg)

SEC 300 mg, ESS = 10

SEC 300 mg, ESS = 17
ACR 50

SEC 150 mg, ESS = 8

SEC 150 mg, ESS = 19

ACR 70

ADA 40 mg, n = 77 (week 24); n = 75 (week 48)

ADA 40 mg, n = 77 (week 24); n = 75 (week 48)

ACR 50

Sensitivity analysis (SEC vs. ADA)

Principal analysis (SEC vs. ADA)

(a)

2.25 (1.37, 3.69) P = 0.001

1.81 (0.82, 3.99)

1.49 (0.69, 3.25)

1.18 (0.33, 4.26)

ACR 70

1.12 (0.45, 2.82)

0.88 (0.27, 2.89)

0.55 (0.10, 3.07)

1.95 (0.79, 4.80)

ACR 70

Table 4 Methotrexate subgroup analysis: comparison of principal and sensitivity analyses in patients (a) receiving and (b) not receiving methotrexate at baseline (relative risks)
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and 50 response rates were significantly higher
for at least one secukinumab dose than for
adalimumab at weeks 16, 24, and 48. In addition, at the week-12 placebo-adjusted time
point, both doses of secukinumab showed a
significantly higher probability of achieving an
ACR 50 response than adalimumab.
PRO Scores
The sensitivity analysis also confirmed the
higher outcomes for secukinumab over adalimumab in HAQ-DI, PGA, and pain scores, as
seen in the principal analysis. In addition, week12 placebo-adjusted secukinumab 300 mg
showed a significantly greater improvement in
HAQ-DI scores from baseline, and there was no
longer any sign of higher outcomes for adalimumab in any of the FACIT-F scores (Table S9
in the supplementary material).
Methotrexate Subgroup Analysis
As shown in Table 4, the results were consistent
with the principal analysis. A consistent statistically significantly higher probability of ACR
20 response rates was seen with secukinumab,
relative to adalimumab, at weeks 24 and 48
(nonplacebo-adjusted).

DISCUSSION
Our study used a methodologically valid MAIC
[10, 51] to assess the comparative effectiveness
of secukinumab versus adalimumab in patients
with active PsA. Although several indirect
comparison methodologies exist, MAIC was
chosen because it allows for a greater degree of
adjustment for cross-trial population differences
than analyses that use only aggregate data.
When populations are well matched [8], it is
possible to compare long-term data beyond the
placebo-controlled phase. This is necessary for
chronic conditions such as PsA because the
short-term placebo-controlled phase of most
RCTs provides only limited data to inform the
mid- to long-term treatment choices; indeed,
several oncology studies have applied MAIC
successfully to long-term patient survival data
[37, 38].
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In the absence of H2H RCT data, MAIC is a
useful surrogate method that is, relative to an
RCT, faster, cheaper, and capable of providing
timely comparative evidence to relevant stakeholders. Nevertheless, observational data generated by MAIC should be viewed as interim to
the reporting of a ‘‘gold-standard’’ H2H RCT,
such as the ongoing EXCEED trial [5].
Our study included both binary (ACR 20, 50,
and 70) and continuous (PRO scores) outcomes
in line with the OMERACT and GRAPPA recommendations [33, 34]. The choice of matching
variables was finalized after consultation with
clinical experts in the spondyloarthritides and
statistical fields, supplemented with empirical
data identifying key effect-modifying variables
[10]. Further baseline characteristics considered
potentially clinically relevant were included in
a sensitivity analysis. We selected adalimumab
as the comparator because of its equivalent
efficacy to other anti-TNFs and widespread
clinical use [19]. Anti-TNFs are established and
recommended treatment options for active PsA
[52–55]. Although there have been no H2H
RCTs between them, indirect retrospective data
suggest that they have similar efficacy and
safety profiles [55, 56]. Meta-analyses have
repeatedly shown no real differences in terms of
ACR outcomes among anti-TNFs [54, 57–60].
Our MAIC indicated that patients treated
with secukinumab had at least an equivalent, or
greater likelihood (depending on time point
and outcome) of experiencing an improvement
in joint signs and symptoms than individuals
treated with adalimumab. In the principal
analysis, both bDMARDs had comparable ACR
responses at week 12 (placebo-adjusted), whilst
we observed several statistically significant
higher responses for secukinumab from week 16
onwards using a nonplacebo-adjusted comparison. The strongest evidence supporting a higher
ACR response with secukinumab was apparent
at weeks 24 and 48 for the 150-mg dose. The
sensitivity analysis replicated the findings of the
principal analysis. Taken together, our analyses
provide a consistent body of evidence suggesting that patients with active PsA treated with
secukinumab (150 or 300 mg) are more likely to
achieve an ACR response through 1 year (weeks
16–48).
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In the principal analysis of PRO data, we
observed significantly improved week-24 HAQDI, PGA, and pain assessments and week-48
HAQ-DI scores for patients treated with secukinumab 150 mg, and a significantly improved
PGA score for secukinumab 300 mg relative to
those treated with adalimumab. Improvement
in pain is considered by PsA patients to be the
most important domain [61]. The improvements estimated for patients treated with
secukinumab 300 mg were similar to those for
individuals treated with adalimumab, for all
time points and all PRO scores, except PGA.
In both of our concomitant MTX subgroups,
we observed that patients receiving secukinumab had a greater likelihood of experiencing
an improvement in joint signs and symptoms,
measured by ACR response criteria at weeks 24
and 48, than did individuals treated with adalimumab. These findings, confirmed by the
sensitivity analysis, suggest that the higher
long-term outcomes for secukinumab compared
with adalimumab for ACR response are independent of MTX use. However, as separate
baseline matching was not performed in subgroups defined by MTX use, we cannot exclude
the possibility that these populations may differ
between the treatment groups.
The data reported in our study differ from a
recently published MAIC analysis that compared IPD of the ADEPT trial with pooled
FUTURE 1 and 2 data [12]. Their primary analysis showed no statistically significant differences in ACR responses between secukinumab
and adalimumab at week 24 (placebo-adjusted)
[12]. However, there are five major methodological limitations in this analysis. First, the
matching parameters did not include previous
anti-TNF exposure, the single most important
observable baseline parameter. This is shown by
regression analysis (Table S4 in the supplementary material), by anti-TNF IR subgroup analysis
of FUTURE 2 [62], and by an earlier analysis of
adalimumab [31]. Second, the analysis was
based on a placebo-adjusted outcome comparison at week 24. This may lead to bias [9, 63]
because by week 24, the respective placebo arms
of both studies had undergone significant population loss at cumulatively unequal rates as a
consequence of different study designs (Fig. 1).
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Third, we consider the use of pooled FUTURE 1
and FUTURE 2 study aggregate data a questionable strategy for short-term comparisons
owing to their differences in loading administration. Fourth, PASI comparisons were made
without being able to match the PASI patient
subgroup. For the same reasons, we opted not to
report PASI outcomes in this publication, as
described in the Methods section above. Fifth,
the other MAIC analysis did not use a linear
predictor scale, for instance ORs or RRs, which is
recommended by MAIC methodology guidelines [10]. Overall, our study goes beyond the
scope of the previously published MAIC [12] in
two main aspects: by providing comparative
effectiveness data for up to 1 year at multiple
time points and for multiple clinical endpoints
and PROs, and by adjusting for previous antiTNF exposure. Despite the above-mentioned
limitations, the results reported in the sensitivity analysis of the previously published MAIC
[12] showed the same trend and are in agreement with our study, i.e., higher ACR 20 and 50
outcomes in anti-TNF-naı̈ve patients receiving
secukinumab compared with adalimumab.
Moreover, two recent publications indicate
favorable sustainability and safety data for
secukinumab [27, 64].
Our MAIC has limitations, both intrinsic to
the methodology and specific to this analysis.
Although observed patient variables at baseline
can be matched, it is not possible to control for
unobserved or unreported variables. Although
both studies were not contemporaneous, a
common issue in comparative analysis, we have
made significant efforts to accommodate differences in study design such as our matching of
appropriate missing data-handling and imputation methods. More specific to our study, the
relatively small ESS used in all of the analyses,
driven by limited overlap between trial populations, must be taken into account when
interpreting our findings. A majority of the
FUTURE 2 patients were effectively lost after
matching (particularly in the sensitivity and
MTX subgroup analyses), and as such, the
findings of this MAIC rely upon a subset of trial
participants. Finally, due to differences in the
study trials regarding the time point from
which placebo-treated patients can receive
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rescue therapy, an unbiased placebo-adjustment
was not possible after week 12. Therefore, we
present nonplacebo-adjusted comparisons that,
while providing a legitimate means to compare
long-term data, do not permit adjustment for
unobserved differences in trial populations or
study design. Given these limitations, our MAIC
analysis is strongest during the placebomatched period, is hypothesis-generating only,
and needs to be confirmed via the ongoing
EXCEED H2H RCT of secukinumab versus
adalimumab in patients with active PsA.

CONCLUSIONS
This MAIC showed evidence suggesting that
patients with active PsA treated with secukinumab and matched to the ADEPT study population have a significantly higher probability
of achieving ACR 20 and 50 response rates
through 1 year than those receiving adalimumab, an effect that appears to be independent of concomitant MTX medication. To
substantiate
these
hypothesis-generating
interim findings, the next level of evidence will
be determined by the ongoing H2H RCT
EXCEED [5].
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